Zai Lab Ltd.

Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. Its products include Zejula, Optune, Qinlock, and Nuzyra. The company was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SHANGHAI and SAN FRANCISCO, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial stage biopharmaceutical company, announced dosing of the first patient in Greater China in the global MAHOGANY study evaluating margetuximab, an investigational, Fc-optimized monoclonal antibody targeting HER2, in combination with a checkpoint inhibitor, with or without chemotherapy, as a potential first-line treatment for patients with HER2-positive gastric cancer (GC) or gastroesophageal junction (GEJ) cancer.

Zai Lab Announces First Patient Dosed in Greater China in the Global Phase 2/3 MAHOGANY Study of Margetuximab in Gastric and Gastroesophageal Junction Cancer

SHANGHAI and SAN FRANCISCO, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial stage biopharmaceutical company, announced dosing of the first patient in China in the global Phase 3 POD1UM-304 study evaluating retifanlimab, an investigational anti-PD-1 antibody, in combination with platinum-based chemotherapy in patients with first-line metastatic non-small-cell lung cancer (NSCLC).

Zai Lab Announces First Patient Dosed in China in a Global Phase 3 Study of Retifanlimab in Patients with NSCLC

Zai Lab raised $761 million in a Hong Kong IPO and rose 8.5% in its first trading session to a market cap of $6.8 billion.

Week In Review: Zai Lab Completes Second Listing With $761 Million HK IPO

SHANGHAI and SAN FRANCISCO, Sept.  28, 2020  (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced listing of its ordinary shares on the Main Board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”) under the stock code “9688” and the closing of its previously-announced Hong Kong secondary listing (the “Hong Kong Secondary Listing”) of 10,564,050 new ordinary shares (the “Offer Shares” or “Shares”) which comprises an international offering (the “International Offering”) and a Hong Kong public offering (the “Hong Kong Public Offering,” and together with the International Offering, the “Offering”). The final offer price for both the International Offering and the Hong Kong Public Offering (the “Offer Price”) has been set at HK$562.00 per Share. Based on the ratio of one (1) ordinary shares per Nasdaq-listed American depositary share (“ADS”), the Offer Price translates to approximately US$72.52 per ADS. The Company had also granted the international underwriters an over-allotment option, exercisable from September 22, 2020 until 30 days thereafter, to require the Company to issue up to an additional 1,584,600 new Shares at the Offer Price.

Zai Lab Announces Closing of Hong Kong Secondary Listing

SHANGHAI, Sept. 27, 2020 /PRNewswire/ -- Qiming's portfolio company Zai Lab (SEHK:9688, NASDAQ:ZLAB), an innovative commercial-stage biopharmaceutical company, officially listed on the Main Board of The Stock Exchange of Hong Kong Limited today. In this secondary listing, the issue price...

Qiming's Portfolio Company Zai Lab Lists on Main Board of HKEX

SHANGHAI and SAN FRANCISCO, Sept.  22, 2020  (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced the pricing of the Hong Kong secondary listing (the “Hong Kong Secondary Listing”) of 10,564,050 new ordinary shares (the “Offer Shares” or “Shares”) which comprises an international offering (the “International Offering”) and a Hong Kong public offering (the “Hong Kong Public Offering”). The final offer price for both the International Offering and the Hong Kong Public Offering (the “Offer Price”) has been set at HK$562.00 per Share. Based on the ratio of one (1) ordinary shares per Nasdaq-listed American depositary share (“ADS”), the Offer Price translates to approximately US$72.52 per ADS. The Company has set the abovementioned offer price by taking into consideration, among other factors, the closing price of the ADSs on September 21, 2020 (the latest trading day before pricing). Subject to approval from The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”), the Shares are expected to begin trading on the Main Board of the Hong Kong Stock Exchange on September 28, 2020 under the stock code “9688” The Hong Kong Secondary Listing is expected to close on the same day, subject to customary closing conditions.

Zai Lab Announces Pricing of Hong Kong Secondary Listing

Week In Review: Zai Lab To Raise Up To $845 Million In Hong Kong IPO

SHANGHAI and SAN FRANCISCO, Sept.  19, 2020  (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced detailed positive results from the NORA study, the Phase 3 randomized, double-blind, placebo-controlled study of ZEJULA (niraparib) as a maintenance therapy in Chinese patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (collectively termed as ovarian cancer) who are in a complete or partial response to platinum-based chemotherapy.

Phase 3 NORA data of ZEJULA® (niraparib) demonstrate significant PFS benefit, regardless of biomarker status, with an improved safety profile when given with individualized starting dose regimen in Chinese women with platinum-sensitive recurrent ovarian c

SHANGHAI and SAN FRANCISCO, Sept.  16, 2020  (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ:ZLAB), an innovative commercial stage biopharmaceutical company, today announced the launch of its Hong Kong public offering (the “Hong Kong Public Offering”), which forms part of the global offering (the “Offering”) of 10,564,050 new ordinary shares (the “Offer Shares” or “Shares”) and listing of its ordinary shares on the Main Board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”) under the stock code “9688”.

Zai Lab Launches Hong Kong Secondary Listing

Du leads Shanghai-based pharma company Zai Lab, whose $6 billion market cap has increased threefold since its IPO valuation on Nasdaq in 2017.

Samantha Du: Meet The Woman Shaking Up China’s Pharmaceutical Market

- ZEJULA is the only PARP inhibitor approved as monotherapy for all-comer patients in the first-line and recurrent maintenance treatment settings regardless of biomarker status

Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China

SHANGHAI and SAN FRANCISCO, Sept.  03, 2020  (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, today announced that detailed clinical data from the NORA Phase 3 study of niraparib have been accepted as a late-breaker oral presentation at the European Society for Medical Oncology (ESMO) 2020 Virtual Congress. Details of the oral presentation are as follows:

Zai Lab Announces Clinical Data to be Presented at ESMO Virtual Congress 2020

SHANGHAI and SAN FRANCISCO, Aug.  31, 2020  (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, today announced that Dr. Samantha Du, Founder, Chairwoman and Chief Executive Officer of Zai Lab, will be presenting at the following upcoming virtual conferences in September. Details of the virtual conferences are as follows:

Zai Lab Announces Upcoming Participation in September Conferences

SHANGHAI and SAN FRANCISCO, Aug.  17, 2020  (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced that F. Ty Edmondson has been named Chief Legal Officer. Mr. Edmondson will lead the global legal and compliance functions reporting to Dr. Samantha Du. Mr. Edmondson joins Zai Lab from Biogen Inc., a leading global biotech company, where he served as Senior Vice President, Chief Corporation Counsel and Assistant Secretary.

Zai Lab Appoints F. Ty Edmondson as Chief Legal Officer

Zai Lab's (ZLAB) CEO Samantha Du on Q2 2020 Results - Earnings Call Transcript

SHANGHAI and SAN FRANCISCO, Aug.  04, 2020  (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced that the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) has granted priority review status to the New Drug Application (NDA) for ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. Ripretinib targets the broad spectrum of KIT and PDGFRα mutations known to drive GIST.

Zai Lab Announces NDA for Ripretinib Granted Priority Review by China’s NMPA

-- Company to host Conference Call and Webcast on August 13, 2020 at 8:00 a.m. ET -- SHANGHAI and SAN FRANCISCO, July  30, 2020  (GLOBE NEWSWIRE) --  Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced it will report financial results for the six months ended June 30, 2020 and corporate updates before the market opens on Thursday, August 13, 2020.

Zai Lab to Announce Financial Results for the Six Months Ended June 30, 2020 and Corporate Updates

China NMPA acceptance of NDA follows recent U.S. FDA approval for the treatment of adult patients with advanced GIST who have received prior treatment with 3 or more kinase inhibitors, including imatinib

China NMPA Accepts NDA Submission of Ripretinib for Advanced Gastrointestinal Stromal Tumor

Zai Lab Granted Exclusive Rights to Develop and Commercialize Repotrectinib in Greater China

Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement for Repotrectinib in Greater China

- The NORA study meets all primary and secondary endpoints

Zai Lab Announces Positive Topline Results from the NORA Phase 3 Study of ZEJULA® as Maintenance Therapy for Chinese Patients with Platinum-sensitive, Recurrent Ovarian Cancer

SHANGHAI and SAN FRANCISCO, May  18, 2020  (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced dosing of the first Chinese patient in the global ATTACK (Acinetobacter Treatment Trial Against Colistin) Phase 3 registrational trial evaluating the combination of sulbactam and durlobactam (SUL-DUR) for the treatment of carbapenem-resistant Acinetobacter baumannii infections.

Zai Lab Announces First Chinese Patient Dosed in the Global Phase 3 ATTACK Trial of Sulbactam-Durlobactam for Patients with Carbapenem-Resistant Acinetobacter Infections

Optune is the first innovative treatment for glioblastoma approved in China in over 15 years

China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma

SHANGHAI, China, and SAN FRANCISCO, May  06, 2020  (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced that the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) has granted priority review status to the New Drug Application (NDA) for omadacycline for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).

Zai Lab Announces NDA for Omadacycline Granted Priority Review by China’s NMPA

There is ridiculously big upside potential for Chinese biotech stocks in the next decade. The spread of the pandemic has only strengthened the case.

This Stock Points to the Massive China Biotech Trend

SHANGHAI, China, and SAN FRANCISCO, April  16, 2020  (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) has granted priority review status to the supplemental New Drug Application (sNDA) for ZEJULA (niraparib) as a maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.

News for Zai Lab Ltd. Stock (ZLAB)